Login to Your Account

Raised Biogen Offer Unlikely to Tempt Facet Shareholders

By Jennifer Boggs

Monday, December 7, 2009
In what it's calling its "best and final offer," Biogen Idec Inc. upped its bid for daclizumab partner Facet Biotech Corp. to $17.50 per share, which values the Redwood City, Calif.-based firm at about $438 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription